Proposal relating to two HIV treatments (Tivicay and Kivexa)

9 September 2016 - PHARMAC is seeking feedback on a proposal to list a new treatment for HIV, dolutegravir (Tivicay) and to amend the listing of a currently funded HIV treatment, abacavir sulphate with lamivudine (Kivexa).

This proposal has arisen as a result of a provisional agreement with GlaxoSmithKline NZ Limited.

In summary, this proposal would result in, from 1 November 2016:

  • Dolutegravir (Tivicay) being funded via Special Authority criteria in the community and DHB hospitals for the treatment of HIV
  • A decrease in the price and subsidy of abacavir sulphate with lamivudine (Kivexa)
  • Delisting and subsidy protection being applied to each of Tivicay and Kivexa

Read PHARMAC Consultation

Michael Wonder

Posted by:

Michael Wonder